---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-209920"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2024-08-29T23:59:59+00:00"
generated_at: "2026-05-31T07:01:39.605252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026

## Summary
- IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.
- Net loss Q2 2024: $17.8M vs $11.3M YoY; R&D expense $12.3M (up 9%).
- Collaboration revenue $0 vs $3.5M in Q2 2023 after Merck deal termination.
- First patient dosed in autoimmune basket trial (AlloNK + rituximab); first LN patient in Phase 1/1b.
- Expect initial AlloNK autoimmune data in H1 2025.

## SEC filing metadata
- accession: 0001193125-24-209920
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2024-08-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/0001193125-24-209920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/d890088d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-209920
- JSON: https://secwatch.observer/filing/0001193125-24-209920.json
- Plain text: https://secwatch.observer/filing/0001193125-24-209920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.